EP1003493A4 - Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales - Google Patents

Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales

Info

Publication number
EP1003493A4
EP1003493A4 EP98938064A EP98938064A EP1003493A4 EP 1003493 A4 EP1003493 A4 EP 1003493A4 EP 98938064 A EP98938064 A EP 98938064A EP 98938064 A EP98938064 A EP 98938064A EP 1003493 A4 EP1003493 A4 EP 1003493A4
Authority
EP
European Patent Office
Prior art keywords
surgical adhesions
rxr agonists
prevent surgical
selective rxr
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938064A
Other languages
German (de)
English (en)
Other versions
EP1003493A1 (fr
Inventor
Xina Nair
Fred Christopher Zusi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1003493A1 publication Critical patent/EP1003493A1/fr
Publication of EP1003493A4 publication Critical patent/EP1003493A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98938064A 1997-07-29 1998-07-28 Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales Withdrawn EP1003493A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5401797P 1997-07-29 1997-07-29
US54017P 1997-07-29
PCT/US1998/015625 WO1999006036A1 (fr) 1997-07-29 1998-07-28 Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales

Publications (2)

Publication Number Publication Date
EP1003493A1 EP1003493A1 (fr) 2000-05-31
EP1003493A4 true EP1003493A4 (fr) 2002-03-27

Family

ID=21988221

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938064A Withdrawn EP1003493A4 (fr) 1997-07-29 1998-07-28 Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales

Country Status (5)

Country Link
EP (1) EP1003493A4 (fr)
JP (1) JP2001511445A (fr)
AU (1) AU733236B2 (fr)
CA (1) CA2295807A1 (fr)
WO (1) WO1999006036A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
WO2007029760A1 (fr) * 2005-09-09 2007-03-15 R & R Inc. Produit pharmaceutique à utiliser dans la prévention et/ou le traitement d’affections abdominales
JP5055971B2 (ja) 2006-11-16 2012-10-24 株式会社ニコン 表面処理方法及び表面処理装置、露光方法及び露光装置、並びにデバイス製造方法
JP2008179570A (ja) * 2007-01-25 2008-08-07 R&R Inc 内臓癒着の予防及び／又は治療のための医薬

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021146A1 (fr) * 1992-04-22 1993-10-28 Ligand Pharmaceuticals Incorporated Composes presentant une activite selective par rapport a des recepteurs de retinoide x
WO1994012880A2 (fr) * 1992-11-25 1994-06-09 La Jolla Cancer Research Foundation Formation d'un homodimere contenant des recepteurs de retinoide x (rxr), composes aromatiques bicycliques pontes et leur utilisation dans la modulation de l'expression genique
EP0694301A1 (fr) * 1994-07-27 1996-01-31 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Mélange synergétique d'au moins un ligand spécifique des RXRs et au moins un ligand spécifique de RAR-alpha
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021146A1 (fr) * 1992-04-22 1993-10-28 Ligand Pharmaceuticals Incorporated Composes presentant une activite selective par rapport a des recepteurs de retinoide x
WO1994012880A2 (fr) * 1992-11-25 1994-06-09 La Jolla Cancer Research Foundation Formation d'un homodimere contenant des recepteurs de retinoide x (rxr), composes aromatiques bicycliques pontes et leur utilisation dans la modulation de l'expression genique
EP0694301A1 (fr) * 1994-07-27 1996-01-31 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Mélange synergétique d'au moins un ligand spécifique des RXRs et au moins un ligand spécifique de RAR-alpha
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9906036A1 *

Also Published As

Publication number Publication date
CA2295807A1 (fr) 1999-02-11
AU8667098A (en) 1999-02-22
EP1003493A1 (fr) 2000-05-31
JP2001511445A (ja) 2001-08-14
WO1999006036A1 (fr) 1999-02-11
AU733236B2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
HRP20000201B1 (en) Prostaglandin agonists and their use to treat bone disorders
PL298493A1 (en) Surgical clip
HUP0002493A3 (en) Use of colchinol derivatives as vascular damaging agents and certain new compounds
IL126592A0 (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthritis and other mmp-mediated disorders
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
GB9722203D0 (en) Surgical clip
EG23980A (en) Potassium salt of (s)-omeprazole
GB9526560D0 (en) Use of 2-Amino-Heterocycles
PT1073416E (pt) Utilização de óxido nítrico inalado como agente anti-inflamatório
ZA957187B (en) Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as medicaments
GB9807464D0 (en) Purification of human acid µ-glucosidase
HUP0203295A3 (en) Treatment of emphysema using pharmaceutical compositions containing rar selective retinoid agonists
ZA957113B (en) Use of N-substituted pyhenothiazines
GB9418762D0 (en) Use of substituted cyclopentane-DI-and-triones
SG42329A1 (en) Use of phenylcyclohexylcarboxamides
EP1003493A4 (fr) Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales
HUP0003845A3 (en) Use of 8a-azalides as antimicrobial agents
GB9525828D0 (en) Use of hetarylacetic acid derivatives
HUP0000483A3 (en) Use of aminoisothiazoles as microbicides
EP1005340A4 (fr) Antagonistes retinoides pour la prevention d'adherences necessitant une intervention chirurgicale
GB9810127D0 (en) Prevention of surgical adhesions
EP0845990A4 (fr) Nouvel emploi de pregnanes-diones comme analgesiques
GB2311723B (en) Sanitary unit free of ligature points
HU9501604D0 (en) Direct neutralization of n-acyl sarlosines
GB9713996D0 (en) Use of salt water

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020208

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/07 A, 7A 61K 31/38 B, 7A 61K 31/335 B, 7A 61K 31/385 B, 7A 61K 31/39 B, 7A 61K 31/19 B

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 41/00 B

Ipc: 7A 61K 31/19 B

Ipc: 7A 61K 31/39 B

Ipc: 7A 61K 31/385 B

Ipc: 7A 61K 31/335 B

Ipc: 7A 61K 31/38 B

Ipc: 7A 61K 31/07 A

RTI1 Title (correction)

Free format text: USE OF SELECTIVE RXR AGONISTS TO PREVENT SURGICAL ADHESIONS

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 41/00 B

Ipc: 7A 61K 31/19 B

Ipc: 7A 61K 31/39 B

Ipc: 7A 61K 31/385 B

Ipc: 7A 61K 31/335 B

Ipc: 7A 61K 31/38 B

Ipc: 7A 61K 31/07 A

RTI1 Title (correction)

Free format text: USE OF SELECTIVE RXR AGONISTS TO PREVENT SURGICAL ADHESIONS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040610